MarketFriction

Pfizer Ltd

NSE PFIZER · BSE 500680 · Pharmaceuticals
₹3,858.90 -0.42%
NSE close2026-10-01
52 week range3,833.50 - 5,578.50
Market cap₹17,901 Cr.
P/E23.3
Price band 20% Delivery 67.8%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales575540547563589538592603642645629653
Expenses393387357385399392364393412417393406
Operating Profit183153189177189146228210230228236248
OPM %32%28%35%32%32%27%38%35%36%35%38%38%
Other Income3644754243432176742-205045
Interest337222332221
Depreciation151814151515161414141514
Profit before tax201176244203215172426260255192269277
Tax %26%26%27%26%26%26%22%26%26%26%26%26%
Net Profit149130179151158128331192189142200204
EPS in Rs32.5628.4139.1032.9434.6127.8972.3441.9141.3231.0043.6844.70
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,5202,570
Expenses1,5791,6161,4681,5161,5781,5261,7751,6161,5551,5401,6151,628
Operating Profit433350501566574712836809638742904942
OPM %22%18%25%27%27%32%32%33%29%33%36%37%
Other Income972321141671838163134185344139116
Interest121211151113158108
Depreciation5863667110310911510662615858
Profit before tax4705175486606426697738247461,016976993
Tax %35%35%34%35%21%26%21%24%26%24%26%
Net Profit305337360429509498613624551768722735
EPS in Rs66.6773.6278.7193.79111.29108.77133.90136.38120.52167.79157.92160.70
Dividend Payout %22%27%25%24%297%32%26%29%29%98%48%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth2%2%1%11%
Compounded Profit Growth10%9%8%14%
Stock Price CAGR7%-7%0%-22%
Return on Equity17%18%16%18%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital464646464646464646464646
Reserves1,9272,1182,3732,6372,9663,3502,3472,8193,1623,5504,1724,157
Borrowings2222226339414010870
Other Liabilities6387228401,0049261,007810997752593585649
Total Liabilities2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922
Fixed Assets944925902950886973894869749713724678
CWIP133151013180820
Investments43370000000000
Other Assets1,6141,9232,3432,7393,0543,4322,3693,0303,2443,5164,1804,224
Total Assets2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity11334532933298323427667356257660968
Cash from Investing Activity68-701-250-238351,530-469-575-3654-71-562
Cash from Financing Activity-1-62-83-110-110-164-1,571-181-346-235-205-798
Net Cash Flow181-417-3-17231,690-1,613-88-2675383-392
Free Cash Flow93398394262125343410654292291783944
CFO/OP62%120%146%105%59%93%89%107%81%64%110%105%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322620293029182023313126
Inventory Days191167148147189198199173175200214195
Days Payable16515717824521319713010291776889
Cash Conversion Cycle5836-10-696318791107154177132
Working Capital Days7-9-47-57-16-83-14124239
ROCE %24%22%17%21%23%20%23%29%26%22%21%24%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
FIIs2.82%3.03%3.32%3.22%3.54%2.74%2.18%2.40%2.60%2.71%2.81%1.65%
DIIs15.00%15.15%15.32%15.83%16.03%16.80%17.10%17.23%17.11%17.05%16.89%17.80%
Public18.24%17.87%17.42%17.00%16.50%16.54%16.79%16.45%16.37%16.32%16.36%16.62%
No. of Shareholders1,16,9481,12,4561,09,2141,06,09898,8241,05,0151,08,2611,03,2221,03,4801,00,93399,5451,02,478

Fundamentals

Market Cap₹ 17,901 Cr.
Current Price₹ 3,913
Stock P/E23.3
Book Value₹ 919
ROCE24.1 %
ROE18.0 %
Dividend Yield1.92 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)11%
Compounded Profit Growth (TTM)14%
Standalone figures.
Valuation
Market capRs 17,655 Cr
Enterprise valueRs 14,614 Cr
P/E (TTM)24.02x
Price to book4.20x
Price to sales6.87x
EV / EBITDA13.81x
EV / EBIT14.61x
EV / sales5.69x
Price to cash flow18.25x
Earnings yield4.16%
Dividend yield1.94%
P/E, 3-year average29.52x
P/B, 3-year average4.94x
P/E, 5-year average29.29x
P/B, 5-year average5.34x
Profitability
Operating margin (excl. other income)35.89%
Operating margin (incl. other income)41.39%
EBITDA margin41.17%
Pre-tax margin38.63%
Net profit margin28.61%
Net margin, latest quarter31.30%
ROE17.16%
ROCE22.92%
ROA14.69%
ROE, 3-year average17.67%
ROCE, 3-year average23.59%
ROA, 3-year average14.96%
ROE, 5-year average19.37%
ROCE, 5-year average25.45%
ROA, 5-year average15.56%
ROIC (approx.)63.73%
Tax rate25.96%
Other income / net worth3.30%
Growth
Sales growth (latest year)10.45%
Profit growth (latest year)-5.88%
Sales CAGR, 3 years1.29%
Sales CAGR, 5 years2.39%
Profit CAGR, 3 years5.01%
Profit CAGR, 5 years7.74%
Sales growth QoQ3.80%
Profit growth QoQ2.33%
Sales growth YoY (latest quarter)8.31%
Profit growth YoY (latest quarter)6.63%
Per share
EPS (TTM)Rs 160.69
EPS (latest year)Rs 157.91
EPS (latest quarter)Rs 44.69
EPS, 3-year averageRs 148.73
EPS, 5-year averageRs 143.29
Book value per shareRs 918.66
Sales per shareRs 561.69
Cash flow per shareRs 211.49
Free cash flow per shareRs 206.34
Dividend per share (latest year)Rs 75.00
Dividend per share, 3-year averageRs 91.66
Dividend per share, 5-year averageRs 70.00
Dividends
Dividend payout47.50%
Dividend payout, 3-year average58.29%
Dividend payout, 5-year average46.07%
Efficiency
Asset turnover0.51x
Fixed asset turnover3.72x
Inventory turnover2.00x
Inventory days182 days
Debtor days26 days
Debtors turnover13.86x
Creditor days89 days
Cash conversion cycle132 days
Working capital days9 days
Leverage
Total debtRs 70 Cr
Cash and bankRs 3,111 Cr
Net debtRs -3,041 Cr
Debt to equity0.02x
Net debt / EBITDA-2.87x
Interest coverage130.11x
Current ratio (filing 2026-03-31)6.06x
Quick ratio (filing 2026-03-31)5.31x
Trade payables (filing 2026-03-31)Rs 216 Cr
Owners' fund to total sources85.39%
Debt to assets1.43%
Cash flow
Cash from Operating Activity (latest year)Rs 968 Cr
Cash from Investing Activity (latest year)Rs -562 Cr
Cash from Financing Activity (latest year)Rs -798 Cr
Net Cash Flow (latest year)Rs -392 Cr
Free cash flow (latest year)Rs 944 Cr
FCFE (approx.: FCF + change in debt)Rs 906 Cr
Cash from ops / profit, 5 years0.89x
Sales to cash flow2.60x
Statement figures
Net sales (TTM)Rs 2,570 Cr
Net sales (latest year)Rs 2,520 Cr
Sales (latest quarter)Rs 653 Cr
Operating profit excl. other income (latest year)Rs 904 Cr
Operating profit (latest quarter)Rs 248 Cr
Other income (TTM)Rs 116 Cr
EBITDA (TTM)Rs 1,058 Cr
PBDT (TTM)Rs 1,050 Cr
Profit before tax (TTM)Rs 993 Cr
Tax (latest year)Rs 253 Cr
Net profit (TTM)Rs 735 Cr
Net profit (latest year)Rs 722 Cr
Net profit (latest quarter)Rs 204 Cr
Depreciation (TTM)Rs 58 Cr
Depreciation (latest quarter)Rs 14 Cr
Interest (TTM)Rs 8 Cr
Cost of goods sold (latest year)Rs 946 Cr
Total expenditure (latest year)Rs 1,615 Cr
Total income (latest year)Rs 2,658 Cr
Share capitalRs 46 Cr
ReservesRs 4,157 Cr
Shareholders' fundsRs 4,203 Cr
Total assetsRs 4,922 Cr
Net blockRs 678 Cr
Capital work in progressRs 20 Cr
ReceivablesRs 182 Cr
InventoryRs 473 Cr
Other liabilitiesRs 649 Cr
Shares outstanding (crore)4.58
Ownership
Promoter holding63.92% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 24.0 is at the 1th percentile of its own 9.4-year range (median 33.8, low 23.6, high 54.0).
P/B 4.20 is at the 7th percentile (median 5.83).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodPFIZERNifty 50Difference
1 week-4.6%-2.8% -1.8 pts
1 month-17.3%-6.8% -10.5 pts
3 months-15.5%-7.6% -7.9 pts
6 months-18.3%+0.4% -18.7 pts
1 year-22.5%-9.9% -12.5 pts
2 years-30.5%-13.6% -16.9 pts
3 years-0.0%+14.2% -14.2 pts
5 years-30.7%+27.9% -58.6 pts
79 mutual fund schemes hold about ₹2,974 Cr. Over three months 72 bought more and 7 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Quant Small Cap Fund2.14%762 +105%
Nippon India Small Cap Fund0.68%565 +19%
ICICI Pru Small Cap Fund1.70%167 +18%
Nippon India Multi Cap Fund0.30%167 +21%
ICICI Pru Small Cap Fund1.70%162 +18%
Nippon India Pharma Fund1.57%149 +19%
ICICI Pru Healthcare Fund-1.86%130 +18%
DSP Healthcare Fund3.22%123 +50%
UTI Mid Cap Fund0.86%110 +18%
DSP Large & Mid Cap Fund0.45%83 +22%
Aditya Birla SL MNC Fund2.19%72 +23%
UTI MNC Fund1.81%51 +109%
Tata India Pharma & Healthcare Fund2.92%45 +38%
UTI Dividend Yield Fund1.19%45 +26%
Quant Healthcare Fund8.83%38 +92%
UTI Small Cap Fund0.53%28 +100%
ICICI Pru MNC Fund1.45%26 +21%
Quant Multi Cap Fund0.33%25 +26%
Bandhan Multi Cap Fund0.69%21 +22%
Tata Multicap Fund0.51%18 +100%
Bandhan Flexi Cap Fund0.23%17 +77%
UTI Healthcare Fund1.11%16 +13%
Aditya Birla SL Pharma & Healthcare Fund1.19%13 +14%
Nippon India Nifty Smallcap 250 Index Fund0.32%11 +21%
NJ ELSS Tax Saver Fund3.13%11 +20%

Red flags

F-score 7 of 8
lookRegulator order or action Regulator order or action 2025-12-24: Pfizer Limited has informed the Exchange about Action(s) taken or orders passed
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2020-02-20Anil GuptaEmployees/Designated Employebuy25Rs 0.01 CrMarket Purchase
2020-02-17Anil GuptaEmployees/Designated Employebuy100Rs 0.04 CrMarket Purchase
2020-02-12Anil GuptaEmployees/Designated Employesell150Rs 0.07 CrMarket Sale
2020-02-04Anil GuptaEmployees/Designated Employebuy25Rs 0.01 CrMarket Purchase
2020-02-03Anil GuptaEmployees/Designated Employebuy125Rs 0.05 CrMarket Purchase
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹653 Cr +8.3% vs Jun 2025. Net profit ₹204 Cr +6.2%.
Against our estimate for Jun 2026: sales -4.2%, profit -2.3% in line. Our estimate for Sep 2026: sales Rs 689 Cr, profit Rs 209 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-17Dividend - Rs 75 Per Share
2025-07-09Dividend - Rs 35 Per Share & Special Dividend Of Rs 100 Per Share/ Special Dividend Of Rs 30
2024-08-21Dividend - Rs 35 Per Share
2023-08-11Dividend - Rs 35 Per Share/ Special Dividend - Rs 5 Per Share
2022-09-19Special Dividend - Rs 30 Per Share
2022-08-18Dividend - Rs 35 Per Share
2021-08-11 Annual General Meeting/Dividend - Rs 30 Per Share/Special Dividend - Rs 5 Per Share
2020-08-27 Annual General Meeting/Dividend - Rs 10 Per Share
2020-05-06 Special Dividend - Rs 320 Per Share
2019-08-01 Dividend - Rs 22.50 Per Share
2018-08-29 Annual General Meeting/Dividend- Rs 20 Per Share
2017-08-22 Dividend Rs 15/- Per Share + Special Dividend Rs 5/- Per Share
2016-06-27 Dividend - Rs.15/- Per Share
2015-07-03Annual General Meeting And Dividend Rs.12.50 Per Share
2014-10-29Annual General Meeting
2013-12-05Interim Dividend - Rs 360/- Per Share
2013-08-28Annual General Meeting / Dividend - Rs 12.50/- Per Share + Special Dividend - Rs 20/- Per Share
2012-07-24Annual General Meeting/ Dividend Rs 12.50 Per Share
2011-07-08Dividend-Rs.4/- Per Share
2011-01-20Interim Dividend-Rs.12.50 Per Share
2010-04-15Div-Rs.12.50 Per Share
2009-03-31Dividend-Rs.12.50/ Per Sh
2008-04-03Agm/Dividend - 275%
2007-03-09Agm/Div-Rs.22.50 Per Sh Purpose Revised
2006-04-10Agm/Div-Rs.10/- Per Share
DateTypeWhat it says
2026-09-29Regulatory actionPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on S...
2026-09-18ResignationResignation of Director/KMP/SMP
2026-09-18ResignationResignation of Director/KMP/SMP
2026-09-18Change in ManagementChange in Management
2026-09-07Board meeting outcomePlease find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
2026-07-29Shareholder meetingVoting results.
2026-07-28Shareholder meetingProceedings of Annual General Meeting held on July 28, 2026
2026-07-28Board meeting outcomePfizer Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-27Director changeChange in Director(s) of the company.
2026-07-17News clarificationThe Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, ...
2026-07-17News clarificationThe Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, ...
2026-07-07UpdatesLetter to shareholders providing the weblink to access the Annual Report for Financial Year 2025 26..
2026-07-06Shareholder meetingNotice of undefined to be held on July 28, 2026
2026-06-05Disclosure under SEBI TakeovPfizer Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac...
2026-05-12Change in ManagementAppointment of Cost Auditor
2026-05-12Shareholder meetingNotice of Annual General Meeting to be held on July 28, 2026
2026-05-12Record DateRecord date for the purpose of Dividend is 17-Jul-2026.
2026-05-12Board meeting outcomePfizer Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-12Board meeting outcomeOutcome of Board Meeting held on May 12, 2026.
2026-04-24Delay/default in the paymentDelay/default in the payment of fines/penalties/dues etc. to authority
2026-04-13Reply to Clarification- FinaThe Exchange had sought clarification from Pfizer Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligat...
2026-03-31Change in ManagementChange in Management
2026-02-09Board meeting outcomePfizer Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-01-20Change in ManagementChange in Management
2026-01-07Clarification - Financial ReThe Exchange has sought clarification from Pfizer Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligat...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Pfizer Ltd?

Pfizer Ltd (PFIZER) has a market capitalisation of Rs 17,901 Cr. at the 2026-10-01 close.

What is the P/E ratio of Pfizer Ltd?

Pfizer Ltd trades at a P/E of 23.3 on trailing twelve-month profit, at the 2026-10-01 close.

What were Pfizer Ltd's latest quarterly results?

In the Jun 2026 quarter, Pfizer Ltd sales was Rs 653 Cr (+8.3% vs Jun 2025) and net profit was Rs 204 Cr.

What is the 52-week high and low of Pfizer Ltd?

The 52-week high is Rs 5,578.50 and the 52-week low is Rs 3,833.50.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03